[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-464930-105":59,"doc-detail-464930-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","nanomedicine-in-ovarian-cancer-advances-in-imaging-targeted-delivery-and-theranostic-therapeutic-platforms","Nanomedicine in Ovarian Cancer: Advances in Imaging, Targeted Delivery, and Theranostic Therapeutic Platforms","","Ovarian cancer remains the most lethal gynaecological malignancy, driven by late-stage diagnosis, extensive peritoneal dissemination, chemoresistance, and constraints of existing imaging and treatment strategies. By optimising pharmacokinetics and refining tumour-selective drug delivery, nanomedicine provides a versatile platform for precise localisation and controlled release. It also advances high-resolution multimodal imaging, integrating diagnosis and therapy through emerging theranostic constructs. Immune-nanomedicine, intraperitoneal depot systems, and nucleic acid-centred nanotherapies address immune suppression and molecular resistance. Clinical translation is limited by complex manufacturing, safety and stability challenges, and limited patient stratification, requiring scalable design innovation, regulatory standardisation, and precision biomarker integration.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/nanomedicine-in-ovarian-cancer-advances-in-imaging-targeted-delivery-and-theranostic-therapeutic-platforms/464930/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/nanomedicine-in-ovarian-cancer-advances-in-imaging-targeted-delivery-and-theranostic-therapeutic-platforms/464930.png","ImageObject",300,407,{"name":92,"@type":93},"Ezra","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-10","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is ovarian cancer still highly lethal despite existing approaches?","Question",{"text":113,"@type":114},"Ovarian cancer remains lethal due to late-stage diagnosis, extensive peritoneal spread, chemoresistance, and limitations of current imaging and therapeutic strategies.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What improvements does nanomedicine offer for imaging and treatment?",{"text":118,"@type":114},"Nanomedicine optimises pharmacokinetics, enhances tumour-selective delivery, supports high-resolution multimodal imaging, and enables integrated diagnosis and therapy through theranostic constructs.",{"name":120,"@type":111,"acceptedAnswer":121},"What strategies are highlighted to address advanced ovarian cancer challenges?",{"text":122,"@type":114},"The review discusses immune-nanomedicine, intraperitoneal depot systems, and nucleic acid-centred nanotherapies aimed at overcoming immune suppression and molecular resistance.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},464930,1791099472,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":4},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Review  \nNanomedicine in Ovarian Cancer: Advances in Imaging, Targeted Delivery, and Theranostic Therapeutic Platforms  \nDorota Bartusik-Aebisher 1, Izabella Wilk 2 and David Aebisher 3, *  \nAcademic Editor: Stefano Leporatti  \nReceived: 7 December 2025  \nRevised: 22 December 2025  \nAccepted: 24 December 2025  \nPublished: 27 December 2025  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Biochemistry and General Chemistry, Collegium Medicum, Faculty of Medicine, University of Rzeszów, 35-310 Rzeszów, Poland; [dbartusikaebisher@ur.edu.pl](dbartusikaebisher@ur.edu.pl)  \n2 English Division Science Club, Collegium Medicum, Faculty of Medicine, University of Rzeszów, 35-310 Rzeszów, Poland; [iw135750@stud.ur.edu.pl](iw135750@stud.ur.edu.pl)  \n3 Department of Photomedicine and Physical Chemistry, Collegium Medicum, Faculty of Medicine, University of Rzeszów, 35-310 Rzeszów, Poland  \n* Correspondence: [daebisher@ur.edu.pl](daebisher@ur.edu.pl)  \nSimple Summary  \nThe major advances in nanomedicine for ovarian cancer are outlined in this review, underlining how engineered lipid, polymeric, inorganic, hybrid and biomimetic platforms improve imaging accuracy, intraperitoneal delivery, and therapeutic precision. Targeted ligands, stimuli-responsive release, and stealth coatings are key design principles which are demonstrated alongside applications in magnetic resonance imaging (MRI), positron emission tomography (PET)/single-photon emission computed tomography (SPECT), nearinfrared imaging (NIR), ultrasound, and multimodal imaging. Nucleic acid nanotherapies, photothermal and enzyme-responsive systems, immune-nanomedicine and intraperitoneal depot strategies are also discussed in this article. The importance of standardisation and personalised nanotherapeutic approaches in ovarian cancer is highlighted by the evaluation of biodistribution, safety, manufacturing, and regulatory framework challenges.  \nAbstract  \nOvarian cancer continues to be the most lethal gynaecological malignancy, principally due to its late-stage diagnosis, extensive peritoneal dissemination, chemoresistance, and limitations of current imaging and therapeutic strategies. By optimising pharmacokinetics, refining tumour-selective drug delivery, and supporting high-resolution, multimodal imaging, nanomedicine offers a versatile platform to address these limitations. In this review, current progress across lipid-based, polymeric, inorganic, hybrid, and biomimetic nanocarriers is synthesised, emphasising how tailored physiochemical properties, surface functionalisation, and stimuli-responsive designs can improve tumour localisation, surmount stromal and ascetic barriers, and enable controlled drug release. Concurrently, significant advancement in imaging nanoprobes, including magnetic resonance imaging (MRI), positron emission tomography (PET)/single-photon emission computed tomography (SPECT), optical, near-infrared imaging (NIR), ultrasound, and photoacoustic systems, has evolved early lesion detection, intraoperative guidance, and quantitative monitoring of treatment. Diagnosis and therapy are further integrated within single platforms by emerging theranostic constructs, encouraging real-time visualisation of drug distribution and treatment response. Additionally, immune-nanomedicine, intraperitoneal depot systems, and nucleic acid-centred nanotherapies offer promising strategies to address immune suppression and molecular resistance in advanced ovarian cancer. In spite of noteworthy achievements, clinical translation is limited by complex manufacturing requirements, challenges with safety and stability, and restricted patient stratification. To unlock the full  \nclinical potential of nanotechnology in ovarian cancer management, constant innovation in scalable design, regulatory standardisation, an","cbCaioAA5173EMDD","https://ap.wps.com/l/cbCaioAA5173EMDD","pdf",10406533,47,"English","# Simple Summary\n# Abstract\n# Keywords\n# 1. Introduction","[{\"question\":\"Why is ovarian cancer still highly lethal despite existing approaches?\",\"answer\":\"Ovarian cancer remains lethal due to late-stage diagnosis, extensive peritoneal spread, chemoresistance, and limitations of current imaging and therapeutic strategies.\"},{\"question\":\"What improvements does nanomedicine offer for imaging and treatment?\",\"answer\":\"Nanomedicine optimises pharmacokinetics, enhances tumour-selective delivery, supports high-resolution multimodal imaging, and enables integrated diagnosis and therapy through theranostic constructs.\"},{\"question\":\"What strategies are highlighted to address advanced ovarian cancer challenges?\",\"answer\":\"The review discusses immune-nanomedicine, intraperitoneal depot systems, and nucleic acid-centred nanotherapies aimed at overcoming immune suppression and molecular resistance.\"}]","Nanomedicine in Ovarian Cancer: Advances in Imaging, Targeted Delivery, and Theranostic Therapeutic Platforms | PDF",1790768929,118]